Eton Pharmaceuticals (ETON) vs Ocular Therapeutix (OCUL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Eton Pharmaceuticals (ETON) has outperformed Ocular Therapeutix (OCUL) over the past year, gaining 159.5% versus a loss of 37.2%. Over five years, ETON leads with a +953.4% price change compared with -35.4% for OCUL. Ocular Therapeutix is the larger company by market cap ($1.64 billion vs $1.56 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ETON | OCUL |
|---|---|---|
| Share price | $54.53 | $7.48 |
| Market cap | $1.56B | $1.64B |
| 1-day change | -0.63% | +3.46% |
| YTD return | +224.54% | -40.44% |
| 1-year return | +159.48% | -37.24% |
| 5-year return | +953.36% | -35.39% |
| P/E ratio (TTM) | 136.33 | — |
| Forward P/E | 21.14 | — |
| EPS (TTM) | $0.40 | $-1.40 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $66.37 | $16.44 |
| 52-week low | $14.27 | $6.23 |
| Distance from 52-week high | -17.83% | -54.50% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +30.19% | +262.17% |
| Average volume | 606.07K | 2.78M |
| Shares outstanding | 28.58M | 219.62M |
| Employees | 44 | 325 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ETON has outperformed OCUL by 196.7 percentage points over the past year.
About Eton Pharmaceuticals
ETON stock →Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1.
Health Care · Biotechnology: Pharmaceutical Preparations · 44 employees
About Ocular Therapeutix
OCUL stock →Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.
Health Care · Biotechnology: Pharmaceutical Preparations · 325 employees
ETON vs OCUL FAQ
Which is bigger, Eton Pharmaceuticals or Ocular Therapeutix?
Ocular Therapeutix (OCUL) is larger, with a market capitalization of $1.64B compared with $1.56B for Eton Pharmaceuticals (ETON).
Which stock has performed better over the past year, ETON or OCUL?
ETON returned +159.48% over the past 12 months, compared with -37.24% for OCUL (price return, excluding dividends). Past performance does not predict future results.
Are Eton Pharmaceuticals and Ocular Therapeutix in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.